178 related articles for article (PubMed ID: 2827353)
21. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus.
Grundy JE; Lui SF; Super M; Berry NJ; Sweny P; Fernando ON; Moorhead J; Griffiths PD
Lancet; 1988 Jul; 2(8603):132-5. PubMed ID: 2899189
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus infection in living-donor and cadaveric lung transplantations.
Ohata K; Chen-Yoshikawa TF; Takahashi K; Aoyama A; Motoyama H; Hijiya K; Hamaji M; Menju T; Sato T; Sonobe M; Takakura S; Date H
Interact Cardiovasc Thorac Surg; 2017 Nov; 25(5):710-715. PubMed ID: 29049752
[TBL] [Abstract][Full Text] [Related]
23. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
Kaufman DB; Leventhal JR; Gallon LG; Parker MA; Koffron AJ; Fryer JP; Abecassis MM; Stuart FP
Transplantation; 2001 Dec; 72(12):1940-5. PubMed ID: 11773893
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
25. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation.
Rubin RH; Tolkoff-Rubin NE; Oliver D; Rota TR; Hamilton J; Betts RF; Pass RF; Hillis W; Szmuness W; Farrell ML
Transplantation; 1985 Sep; 40(3):243-9. PubMed ID: 2994266
[TBL] [Abstract][Full Text] [Related]
26. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center.
Preiksaitis JK; Sandhu J; Strautman M
Transfusion; 2002 Apr; 42(4):396-402. PubMed ID: 12076284
[TBL] [Abstract][Full Text] [Related]
27. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
28. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience.
Balk AH; Weimar W; Rothbarth PH; Meeter K; Metselaar HJ; Mochtar B; Simoons ML
Infection; 1993; 21(4):195-200. PubMed ID: 8225620
[TBL] [Abstract][Full Text] [Related]
29. The effect of cyclosporine on early graft function in human renal transplantation.
Flechner SM; Payne WD; Van Buren C; Kerman R; Kahan BD
Transplantation; 1983 Sep; 36(3):268-72. PubMed ID: 6351368
[TBL] [Abstract][Full Text] [Related]
30. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
31. The influence of donor factors other than serologic status on transmission of cytomegalovirus to transplant recipients.
Chou SW; Norman DJ
Transplantation; 1988 Jul; 46(1):89-93. PubMed ID: 2839917
[TBL] [Abstract][Full Text] [Related]
32. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients.
Boudreaux JP; McHugh L; Canafax DM; Ascher N; Sutherland DE; Payne W; Simmons RL; Najarian JS; Fryd DS
Transplantation; 1987 Sep; 44(3):376-81. PubMed ID: 3307061
[TBL] [Abstract][Full Text] [Related]
33. The problem of cytomegalovirus infection in renal allograft recipients.
Kurtz JB; Thompson JF; Ting A; Pinto A; Morris PJ
Q J Med; 1984; 53(211):341-9. PubMed ID: 6091169
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalo and herpes simplex virus infections in renal transplant recipients.
Wertheim P; Slaterus KW; Geelen JL; van der Noordaa J; Wilmink JM
Scand J Urol Nephrol Suppl; 1985; 92():5-8. PubMed ID: 3008317
[TBL] [Abstract][Full Text] [Related]
35. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J
Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
[TBL] [Abstract][Full Text] [Related]
36. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
37. Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts.
Tilney NL; Chang A; Milford EL; Whitley WD; Lazarus JM; Ramos EL; Strom TB; Carpenter CB; Kirkman RL
Ann Surg; 1991 Jul; 214(1):42-9. PubMed ID: 2064470
[TBL] [Abstract][Full Text] [Related]
38. Cytomegalovirus infection after kidney transplantation using cyclosporin A and low-dose prednisolone immunosuppression.
Mayer G; Watschinger B; Pohanka E; Graf H; Popow T; Ulrich W; Kovarik J
Nephrol Dial Transplant; 1988; 3(4):464-8. PubMed ID: 2845305
[TBL] [Abstract][Full Text] [Related]
39. Gancyclovir prophylaxis in high risk patients.
Campino A
Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106
[TBL] [Abstract][Full Text] [Related]
40. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
Shah AP; Chen JM; Fridell JA
Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
